-
Xiaomi Pad 9 Pro Leak Suggests 12.5-Inch Display and Massive Battery
-
China's Xi and Iran's Pezeshkian in Kyrgyzstan, Putin expected
-
UK Homeowners Advised to Use Peppermint Tea Bags to Deter Spiders
-
Rescuers hunt for missing after deadly N.Cyprus ferry accident
-
Nepal toll surges as rescuers struggle through 'unimaginable' disaster
-
Ethiopia's Abiy could consolidate power as 'executive president'
-
Mauled Australian swimmer recalls punching shark
-
Crude prices rise on US-Iran strikes, equities mixed after Warsh remarks
-
Passengers stranded overnight by Kenya airport strike
-
South Korea court gives Unification Church leader 2 years prison
-
Nepal recovers bodies but presses on for trapped tunnel workers
-
US hosts G20 finance talks with growth, Iran pressure on agenda
-
Grand Canyon flash flood leaves one dead, around 15 missing
-
African players in Europe: Wissa flick seals Newcastle victory
-
Venus Williams falls at first hurdle in US Open
-
Venice film preview: Clooney, Oasis and Musk
-
At least five leaders skip annual Pacific Islands summit
-
Poorly Djokovic crashes out of US Open first round
-
I.Coast home-hunters' saga highlights Africa housing crunch
-
Djokovic falls in US Open first round, earliest Grand Slam exit in 20 years
-
At least five leaders to skip annual Pacific Islands summit
-
Chinese guitar capital's stairway to export heaven
-
Latest developments in the US-Iran war
-
Stocks drop as Warsh fans US rate hike bets, crude up on US-Iran strikes
-
Nepal buries dead as rescuers seek thousands missing
-
Injuries cloud tennis as US Open gets under way
-
From Montecito to the Cotswolds: Harry and Meghan eye new UK home
-
Iran retaliates after first US strikes in a month
-
Russia's Putin and China's Xi to attend summit in Kyrgyzstan
-
Itauma says 'I'll be back' after bruising heavyweight title loss
-
John Ternus to lead Apple into the age of AI
-
Brilliant Palou clinches fourth straight IndyCar crown
-
Trump calls for 'punishment' of NBC reporter
-
EN China XLX Announces 2026 Interim Results
-
US strikes Iran for first time in a month, Tehran retaliates
-
About 15 people missing after Grand Canyon flash flood
-
Yin holds off Kim to win sixth LPGA title, end title drought
-
Medvedev advances without drama at US Open
-
Top-ranked Scheffler storms to PGA Tour Championship win
-
Calhanoglu fires Inter to nervy Cagliari win, Como stun Napoli
-
Root urges England to be 'grown-ups' after Pakistan series win
-
Monaco beat Marseille to go top, Rosenior's Paris FC thump Nice
-
Google Maps renames Lake Ontario 'Lake America' in US -- but not Canada
-
Pegula shakes off nerves in US Open first-round win
-
Aaron Donald ends retirement to rejoin Rams: team
-
FIFA president Infantino 'must go', says ex-UEFA boss Platini
-
Niamey back to normal after soldiers' mutiny
-
England v Pakistan second Test: Three talking points
-
Niger mutiny suppressed, but questions remain over junta's cohesion
-
Rashford's return 'fantastic' for Man Utd, says Carrick
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto International Conference Center. This includes three oral presentations and two poster presentations across the Company's propionic acidemia (PA), methylmalonic acidemia (MMA) and Glycogen Storage Disease Type 1a (GSD1a) programs. This is the first time Moderna will present data at a scientific congress for MMA and GSD1a.
The details of the presentations are as follows:
Oral Presentation #8 - Organic Acidemias: Clinical Burden of Propionic Acidemia in Japan: A real-world evidence cohort study using a hospital-based healthcare database
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 1
Location: Room 5
Presenter: Yoko Nakajima
Oral Presentation #8 - Organic Acidemias: mRNA-3705 Therapy for Methylmalonic Acidemia: Interim Data from a Phase 1/2 Study
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 7
Location: Room 5
Presenter: Sabine Fuchs
Oral Presentation #8 - Organic Acidemias: mRNA-3927 for the Treatment of Propionic Acidemia: Final results from mRNA-3927-P101 Part 1 dose-escalation cohorts and cumulative data from ongoing participants
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 8
Location: Room 5
Presenter: Andreas Schulze
Poster Presentation #P-521: Model-Informed Dose Selection for the Pivotal Study of mRNA-3705 in Methylmalonic Acidemia
Time: Wednesday, September 3, 2025, 6:00 - 7:00 PM JST
Location: Poster 1 - Annex Hall
Presenter: Min Liang
Poster Presentation #P-246: mRNA-3745 Therapy for GSD1a: Interim reported data from Phase 1/2 Ba1ance Study
Time: Thursday, September 4, 2025, 5:30 - 6:30 PM JST
Location: Poster 1 - Annex Hall
Presenter: Nicola Longo
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
P.A.Mendoza--AT